Thera-SAbDab

ROZIPAFUSP

>   Structural Summary
TherapeuticRozipafusp
TargetICOS
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK
100% seqID Fv Structure6x4t [Fvs: BE, DF]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb Fusion
IsotypeG2
Highest Clinical Trial (August '23)Phase-I
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year RecommendedNone
Companies InvolvedAmgen
Conditions Approvedna
Conditions ActiveRheumatoid arthritis
Conditions DiscontinuedSystemic lupus erythematosus
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy